Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

14.2K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
14.2K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

6.5K
The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
6.5K
cAMP-dependent Protein Kinase Pathways01:25

cAMP-dependent Protein Kinase Pathways

9.4K
Cyclic Adenosine Monophosphate (cAMP) is an essential second messenger that activates protein kinase A (PKA) and regulates various biological processes. A single epinephrine molecule binds to GPCR and activates several heterotrimeric G proteins, each stimulating multiple adenylyl cyclase, amplifying the signal, and synthesizing large numbers of cAMP molecules. Small changes in cAMP concentration affect PKA activity. The binding of four cAMP molecules induces a conformational change in PKA,...
9.4K
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

5.7K
5.7K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

6.3K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
6.3K
Inhibitors of Viral Protein Synthesis01:30

Inhibitors of Viral Protein Synthesis

37
Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
37

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Discovery and Characterization of GLPG3808, a PAPD5/7 Inhibitor for Suppression of Hepatitis B Viral Infections.

Journal of medicinal chemistry·2026
Same author

HBsAg Suppression by a New Series of HBV RNA Destabilizers: Discovery and Effects on In Vitro Neurite Outgrowth.

Journal of medicinal chemistry·2026
Same author

Discovery of GLPG4471, a potent and selective IRAK4 inhibitor for the treatment of inflammatory and autoimmune diseases.

Bioorganic & medicinal chemistry letters·2025
Same author

Discovery of Potent and Brain-Penetrant Bicyclic NLRP3 Inhibitors with Peripheral and Central In Vivo Activity.

Journal of medicinal chemistry·2025
Same author

Design of a potent and selective dual JAK1/TYK2 inhibitor.

Bioorganic & medicinal chemistry·2024
Same author

Discovery of GLPG3667, a Selective ATP Competitive Tyrosine Kinase 2 Inhibitor for the Treatment of Autoimmune Diseases.

Journal of medicinal chemistry·2024

Related Experiment Video

Updated: Apr 17, 2026

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors
12:40

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

Published on: December 7, 2014

15.4K

Progress toward JAK1-selective inhibitors.

Christel J Menet1, Oscar Mammoliti, Miriam López-Ramos

  • 1Department of Medicinal Chemistry, Generaal de Wittelaan L11A3, 2800 Mechelen, Belgium.

Future Medicinal Chemistry
|February 17, 2015
PubMed
Summary

Selective JAK1 inhibition shows therapeutic potential for autoimmune diseases. Targeting Janus kinase 1 (JAK1) offers a promising approach for treating conditions like rheumatoid arthritis and myelofibrosis.

Area of Science:

  • Cell Biology
  • Immunology
  • Pharmacology

Background:

  • The Janus kinase-signal transducer and activator of transcription (JAK-STAT) pathway is crucial in cellular signaling.
  • JAK inhibitors have transformed the treatment of autoimmune diseases, with several approved and many in development.
  • Selective targeting of specific JAK family members is an emerging therapeutic strategy.

Purpose of the Study:

  • To review the current research on selective Janus kinase 1 (JAK1) inhibition.
  • To highlight the critical role of JAK1 in cytokine signaling pathways.
  • To discuss the therapeutic potential of JAK1-selective inhibitors.

Main Methods:

  • Literature review of preclinical and clinical studies.
  • Analysis of signaling pathways involving JAK1, including gamma-c (γc) cytokine and Interleukin-6 (IL-6) signaling.

More Related Videos

Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3
08:36

Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3

Published on: April 7, 2023

1.7K
Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays
13:22

Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays

Published on: October 23, 2019

8.4K

Related Experiment Videos

Last Updated: Apr 17, 2026

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors
12:40

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

Published on: December 7, 2014

15.4K
Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3
08:36

Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3

Published on: April 7, 2023

1.7K
Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays
13:22

Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays

Published on: October 23, 2019

8.4K
  • Evaluation of the efficacy and safety profiles of JAK1-selective inhibitors.

    • Main Results:

    • JAK1 is a key mediator in the signaling of γc cytokines and IL-6.
    • Selective JAK1 inhibition demonstrates significant therapeutic potential in preclinical models of autoimmune diseases.
    • Ongoing clinical trials are evaluating the efficacy of JAK1-selective agents.

    Conclusions:

    • Selective JAK1 inhibition represents a promising therapeutic strategy for autoimmune and inflammatory conditions.
    • Understanding the specific roles of JAK family members allows for more targeted drug development.
    • Further research into JAK1-selective therapies could lead to improved treatment outcomes.